Full Press Release Details
Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation
Intellectual Property Portfolio Enables Acceleration of Business Development Activities
Aviv, Israel August 6, 2020 - Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology
which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual
Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034,
subject to patent term adjustment or extension.
is a pivotal event for Cellect and perhaps one of the most crucial developments for us as we have secured IP protection over the
second component of the ApograftTM effects - the activation of the stem and progenitor cells," commented
Dr. Shai Yarkoni, Chief Executive Officer. "While the extensive issued patents cover the accurate elimination (negative
selection) of the mature cells and therefor enables SAFETY, this patent covers the increased ACTIVITY
(positive selection=efficacy) of the regenerative capacity of the stem and progenitor cells. Combined with our previously issued
patents, our IP now cover the dual effects of the apoptotic proteins with a single, robust, and cost-effective process that is
achieved outside of the patient's body. The clinical and economic benefits are multi-fold as we have demonstrated increased
safety and efficacy of the cell product by developing a robust, non-expensive and user-friendly process and product.
actions over the past few years to strengthen our IP, culminating with this very important achievement, has been a core component
of our business strategy and has far-reaching revenue and business development activities. While some of these discussions are
and have been underway for some time with global leaders in cell therapy, it's quite obvious we are now in a much stronger
position to leverage our innovation to extract tremendous value."
patent, which was also recently approved in Australia and Israel, includes a cell-based product and a method of manufacturing
a stem and progenitor cell population with enhanced activity by incubation with an apoptotic ligand at specific
concentrations and exposure times. The Company has an extensive Intellectual Property (IP) portfolio, with 65 patents in nine
patent families, with 45 already granted/allowed patents, 18 pending/in examination and two Patent Cooperation Treaty (PCT)
applications. The Company plans to continue expanding and protecting its global IP to monetize its investments, either
internally or externally, and to create further barriers to entry
Cellect Biotechnology Ltd.
Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims
to improve a variety of stem cell-based therapies.
Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate
stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative
medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.
press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements
can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",
"may", "should", "could", "might", "seek", "target", "will",
"project", "forecast", "continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example,
forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement
of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications
are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical
results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar
conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking
statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain
additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash
flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability
to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may
not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to
timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain
strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain
for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of
others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the
Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development
of its products; and the Company's ability to pursue any strategic transaction or that any transaction, if pursued, will
be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company
undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future
developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks
and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s
Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission,
or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC.
Leibovitz, Chief Financial Officer